Expert Group meeting with the management of EGFR mutation positive NSCLC - Part II

Speciality: Ophthalmology


Speaker:

Dr. Abhishek Bansal ( Panelist ) | Consultant Medical Oncologist, SSB Heart And Multispeciality Hospital, Fridabad.

Dr. Atul Sharma ( Panelist ) | Senior Consultant Medical Oncologist, Jaypee Hospital, Noida

Dr. Vineet Govinda Gupta ( Moderator ) | Senior Consultant Medical Oncologist

Description:

A warm welcome to all the medical professionals in this interesting session on Expert group convenes to discuss management strategies for EGFR mutation-positive NSCLC.

The Expert Group meeting on the management of EGFR mutation-positive non-small cell lung cancer (NSCLC) convenes to address critical aspects of treatment strategies, therapeutic advancements, and patient care. Participants, including leading oncologists, researchers, and healthcare professionals, gather to discuss the latest developments in targeted therapies, molecular diagnostics, and personalized medicine for patients with EGFR mutation-positive NSCLC.

The meeting aims to foster collaboration, exchange scientific insights, and explore innovative approaches to optimize patient outcomes and quality of life. Through comprehensive discussions, evidence-based presentations, and case studies, the Expert Group endeavors to refine treatment algorithms, identify emerging challenges, and propose novel solutions to enhance the standard of care for individuals affected by EGFR mutation-positive NSCLC.

Ultimately, the collaborative efforts of the Expert Group contribute to advancing the field of oncology and improving the prognosis and management of EGFR-driven NSCLC.

Therefore, get an overall knowledge on Expert group convenes to discuss management strategies for EGFR mutation-positive NSCLC. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

2.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

3.

What Role Should Genomic Classifier Testing Play in Prostate Cancer?

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

Squeezing through tiny blood vessels may trigger melanoma cells to spread


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot